SANTA MONICA, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver ...

THE problem of wasting ascites occurring in patients with cirrhosis of the liver is unsolved — both the pathogenesis of the ascites and its reliable cure. Recent observations have indicated the ...

W. L. Gore & Associates has reported the enrollment of the first patient in the Gore Early TIPS for Ascites Study at the Indiana University Hospital in Indianapolis. The objective of the study, which ...

Splenomegaly resulting from portal hypertension can be caused by cirrhosis, hepatic venous outflow tract obstruction and extrahepatic portal vein obstruction. Both cirrhosis and hepatic venous outflow ...

CARSON CITY, Nev., March 13, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of ...

Investigators assessed the long-term outcomes of patients with cirrhosis and ascites switched from treatment with propranolol to carvedilol. Patients with cirrhosis and ascites had improved renal ...

Early initiation of diuretic therapy in patients with new onset cirrhotic ascites lowers 90-day mortality rate, according to a study in the American Journal of Gastroenterology. Researchers examined ...

Challenges in developing drugs for pancreatic ductal adenocarcinoma (PDAC) include obtaining metastatic cancer tissue for research and validating biomarkers predicative for personalised therapeutic ...

This 29-year-old man developed new-onset ascites while in hospital. The patient has HIV infection, first diagnosed in 1994. He has been poorly compliant with his highly active antiretroviral therapy ...

SANTA MONICA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today ...